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Targeting epigenetic processes in 
photodynamic therapy-induced 
anticancer immunity
Malgorzata Wachowska , Angelika Muchowicz  and Jakub Golab *
Department of Immunology, Medical University of Warsaw, Warsaw, Poland
Photodynamic therapy (PDT) of cancer is an approved therapeutic procedure that 
generates oxidative stress leading to cell death of tumor and stromal cells. Cell death 
resulting from oxidative damage to intracellular components leads to the release of 
damage-associated molecular patterns (DAMPs) that trigger robust inflammatory 
response and creates local conditions for effective sampling of tumor-associated 
antigens (TAA) by antigen-presenting cells. The latter can trigger development of 
TAA-specific adaptive immune response. However, due to a number of mechanisms, 
including epigenetic regulation of TAA expression, tumor cells evade immune rec-
ognition. Therefore, numerous approaches are being developed to combine PDT 
with immunotherapies to allow development of systemic immunity. In this review, 
we describe immunoregulatory mechanisms of epigenetic treatments that were
shown to restore the expression of epigenetically silenced or down-regulated major 
histocompatibility complex molecules as well as TAA. We also discuss the results 
of our recent studies showing that epigenetic treatments based on administration 
of methyltransferase inhibitors in combination with PDT can release effective mech-
anisms leading to development of antitumor immunity and potentiated antitumor 
effects.
 
Keywords: photodynamic therapy, cancer, immunotherapy, epigenetic mechanisms, histone deacetylase, 
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introduction
Photodynamic therapy (PDT) is a light-based therapeutic approach used for the treatment of 
various solid tumors and non-malignant diseases. Its mechanism of action involves three non-
toxic and harmless components: photosensitizer (PS), light, and oxygen. Their spatiotemporal 
encounter triggers photochemical reaction leading to formation of singlet oxygen and ensuing 
photodamage in tumor tissue (1). PS can be applied topically or administered systemically. After 
a period allowing for PS accumulation within the tumor, light of appropriate wavelength is 
precisely delivered to tumor site, usually from laser sources. Light activates PS from its ground 
state to the excited triplet state. Activated PS transfers its energy to molecular oxygen, leading to 
generation of highly reactive singlet oxygen, or reacts directly with biomolecules forming free 
radicals such as superoxide ion, hydroxyl radical, or hydrogen peroxide. These reactive oxygen 
species (ROS) mediate oxidative damage of intracellular macromolecules causing tumor cell 
death (2, 3).
July 2015 | Volume 5 | Article 1762
Wachowska et al. Epigenetics and PDT in cancer immunotherapy
Frontiers in Oncology | www.frontiersin.org
Photodynamic Therapy and  
Anticancer immunity
Direct cytotoxic effects induced by PDT do not explain strong 
antitumor activity of this treatment observed in experimental 
animals. For example, cells from the tumors excised immediately 
after curative PDT are still clonogenic indicating that there must 
be other, indirect mechanisms triggered by PDT that contribute 
to the efficacy of the treatment (4). These indirect mechanisms 
include disruption of tumor vasculature, leading to oxygen and 
nutrient deprivation, and induction of robust inflammatory 
reaction, which can further stimulate development of antitumor 
immune responses (5, 6). A critical role in the therapeutic outcome 
of PDT is played by the immune system. Studies in immunode-
ficient mice or in mice inoculated with lymphocyte-depleting 
antibodies revealed that the presence of effector immune cells is 
necessary for maximum therapeutic response (7–9).
innate immune Response in PDT
Massive PDT-induced photooxidative damage occurs mainly in 
the membranes and cytoplasm of tumor cells, tumor vasculature, 
and other stromal elements. This substantial PDT-mediated 
local injury threatens the host tissue integrity and homeostasis. 
Therefore, a host response develops as acute local inflamma-
tion in order to eliminate dead and injured cells, heal lesion, 
and restore tissue function as well as maintain its homeostasis 
(8). This response is induced almost instantaneously following 
PDT. Triggered by massive cell death, release of cytoplasmic 
components, vasoactive substances, as well as activation of the 
complement cascade, it leads to the secretion of leukocyte chem-
oattractants, cytokines, growth factors, and other immunoregula-
tors that lead to a robust infiltration of the tissue with neutrophils, 
mast cells, macrophages, and NK cells (10).
A number of cytokines have been detected both within the 
tumor and in the plasma of mice undergoing PDT. Among a 
wide range of cytokines (IL-1β, IL-6, IL-10, TNF, and G-CSF) 
and chemokines (KC and MIP2) induced after PDT, a very 
important role is assigned to IL-1β and IL-6 (11). Neutralization 
of IL-1β reduces the cure rates of PDT-treated tumors, whereas 
no significant effects are observed with anti-TNF-alpha and 
anti-IL-6 antibodies (12). Also, recombinant cytokines such as 
G-CSF, GM-CSF, and TNF combined with PDT enhance anti-
tumor response (13–15), whereas blocking anti-inflammatory 
cytokines such as IL-10 and transforming growth factor-β  
(TGF-β) improves the cure rates of PDT-treated tumors (8).
Neutrophils are the first cells invading PDT-treated tumor sites 
showing remarkable impact on PDT-mediated tumor damage. It 
was shown that neutrophils depletion in tumor bearing mice and 
rats attenuates the efficacy of antitumor PDT (16, 17). Monocytes/
macrophages infiltrating tumor bed also seem to participate in 
regulating the outcomes of PDT. Inactivation of macrophages with 
silica particles decreases cure rates in mice, whereas treatment 
with macrophage-activating factor Vitamin D3-binding protein 
or GM-CSF potentiates antitumor effects of PDT (13, 18). Role of 
innate immune response in antitumor PDT is also associated with 
activity of NK cells. Depletion of NK cells significantly inhibits 
the response to PDT at suboptimal dose (19).
Innate immune cells encounter released tumor antigens 
(including oxidatively modified ones) together with molecules 
known as damage-associated molecular patterns (DAMPs) or 
cell death-associated molecular patterns (CDAMPs) (9). DAMPs 
play an analogous role to pathogen-associated molecular patterns 
(PAMPs), serving as warning signals. Recognition of PAMPs 
leads to initiation of the pathogen-induced responses, whereas 
DAMPs promote inflammatory responses to cell stress, injury, 
or death. DAMPs bind to pattern recognition receptors (PRRs) 
on the surface of infiltrating leukocytes and activate antigen-
presenting cells (APCs) to stimulate innate and adaptive immu-
nity. Therefore, DAMPs released from PDT-treated tumor cells 
are believed to be the key players in the immunogenicity of tumor 
cells (20, 21). The best known and frequently reported examples 
of PDT-induced DAMPs include heat-shock protein (HSP) fam-
ily (HSP70 and HSP90), high mobility group box-1 (HMGB-1), 
adenosine triphosphate (ATP), and calreticulin (CRT).
Adaptive immune Response in PDT
It was demonstrated that the degree of PDT-mediated inflam-
mation influences adaptive immune response and generation of 
antitumor immunity (22). The link between innate and adaptive 
immune response is dendritic cells (DCs), the most potent APCs, 
capable of migrating to secondary lymphoid tissues to prime T 
cells (23). PDT that triggers necrotic and apoptotic tumor cell 
death, accompanied by oxidative stress and induction of HSPs, 
is believed to shape a unique environment with tumor antigens 
and “danger” signals activating DC maturation (24, 25). It was 
shown that PDT-elicited local and systemic inflammation results 
in attraction of DCs to the tumor site, their activation, and 
maturation (24, 26, 27). DCs that have captured tumor-derived 
proteins and encounter DAMPs undergo activation and func-
tional maturation, migrate to the tumor-draining lymph nodes, 
where they present tumor-associated antigens (TAA) in associa-
tion with major histocompatibility complex (MHC) class I and II 
molecules to T lymphocytes. This allows selection, proliferation, 
and differentiation of the rare antigen-specific T lymphocytes into 
effector T cells (28). During effective adaptive antitumor immune 
response, activated T cells return to the circulation in order to 
home to the tumor site to carry out their effector functions 
(29). There are several independent studies underscoring the 
role of effector CD8+ cytotoxic T cells (CTLs) in PDT outcome. 
Long-term tumor control after PDT treatment is possible only in 
immunocompetent mice, whereas in immunodeficient SCID or 
nude mice the long-term effects are abrogated. However, adoptive 
transfer of T cells from normal mice that underwent successful 
PDT restores antitumor PDT efficacy in immunodeficient ani-
mals. Importantly, T-cell depletion studies revealed that the CD8+ 
T-cell population is critical for a successful PDT response whereas 
CD4+ T cell population plays only a supportive role (19).
Several reports describe the essential role of CD8+ T cells also 
in clinical PDT efficacy. Tumors lacking MHC class I on their 
surface are resistant to specific antitumor immune response 
since recognition of MHC I is necessary for CD8+ T cell activa-
tion (30). Moreover, PDT of multifocal angiosarcoma resulted in 
spontaneous regression of untreated distant tumors accompanied 
by increased infiltration with CD8+ T cells (31).
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Tumor escape Mechanisms from  
immune Surveillance
There is a strong evidence from mouse and human studies for the 
existence of antitumor immune response. However, tumor cells 
engage diverse mechanisms to modulate the immune response 
and to evade recognition and elimination by effector lymphocytes 
(32). “Cancer immunoediting” concept was proposed to describe 
the interactions between tumors and the immune system. 
According to this paradigm tumors are kept under surveillance 
of the immune system that either eliminates nascent tumor cells 
or keeps them at check in the so called equilibrium. But this 
protective response also shapes transformed cells in the “immu-
noediting” process to select for variants that develop escape 
mechanisms mitigating development of an effective antitumor 
immune response (33). A variety of mechanisms develop in 
tumors to avoid recognition by cells of the immune system. These 
mechanisms can be either inherent to tumor cells themselves or 
develop in stromal compartment.
Defective Antigen Presentation
Presentation of TAA to lymphocytes is critically dependent on 
the multiple components of the antigen processing machinery 
(APM). It consists of four major steps: (1) peptide processing, 
(2) peptide transport, (3) MHC class I assembly, and (4) antigen 
presentation (34). A fundamental mechanism resulting from 
immunoediting and allowing tumor cells to evade immune 
surveillance is associated with down-modulation of APM. The 
loss of MHC class I antigens is one of the most frequent way to 
evade immune recognition (35, 36). Total loss of MHC I may be 
a result of structural changes in the β2-microglobulin gene result-
ing from mutations, deletion or loss of heterozygosity. Whereas 
decreased expression of these molecules largely depends on the 
regulation of transcriptional processes, involving epigenetic 
modulation (see below). Impaired APM can also be caused by 
decreased expression of proteasome subunits LMP-2 LMP-7, and 
LMP-10 down-regulation of proteasome activator PA28, peptide 
transporters TAP-1, and TAP-2 as well as chaperones tapasin 
and calnexin. These phenomena are observed in various types of 
tumors both in mice and humans, often in metastases (35, 37–39).
Another mechanism of insufficient antigen presentation 
involves loss or down-regulation of potentially immunogenic 
TAA expression. In melanoma, tumor development is frequently 
related to low level of TAA (32). Similarly, reduced expression of 
MUC-1 antigen is observed in human breast cancer cells. CD8+ T 
lymphocytes isolated from patients with low expression of MUC1 
do not react to autologous tumors (40). Molecular mechanisms 
responsible for changes in MHC expression on tumor cells 
include several types of gene modifications. However, in  vitro 
studies show that loss of one allele or haplotype occurs very 
rarely (41). Therefore, it is suggested that tumor cells engage dif-
ferent strategies affecting antigen presentation in order to escape 
from immune recognition. Recent studies emphasize the role of 
epigenetic changes not only in tumor development and progres-
sion but also in tumor evasion (42, 43). It seems that epigenetic 
modifications play a key role in regulation of MHC, APM, and 
TAA expression level in tumor cells.
Tolerance, Deviation, and Adaptation
Although tumor cells, with rare exception of hematologic 
malignancies, do not express co-stimulatory molecules, they 
can express inhibitory molecules, such as PD-L1, PD-L2, 
LAG-3, TIM3, BTLA-4, or VISTA that induce deletion or anergy 
of tumor-reactive T cells. Some of these molecules as well as 
tumor-expressed FasL (CD95L/Apo1L) can also induce cell death 
in both T and NK cells. Another related mechanism is associated 
with surface expression of non-classical MHC class I molecules 
HLA-G and HLA-E that inhibit cytotoxic activity of effector CTLs 
and NK cells (44–46). Circulating MICA and MICB molecules, 
ligands for NKG2D receptor attenuate effector capacity of T 
lymphocytes and NK cells (47).
Suppressed antitumor immune response may be a result of 
tumor-induced changes in the function of DCs. Human and 
mouse tumors release cholesterol metabolites down-regulating 
the expression of CCR7 receptor on maturing DCs. This inhibits 
CCR7-dependent DC migration to lymphoid organs (48). 
Moreover, tumor cells produce vascular endothelial growth fac-
tor (VEGF) responsible not only for tumor angiogenesis, but also 
for impairment of DC maturation. Treatment with monoclonal 
antibodies against VEGF improves DC function in  vivo and 
the efficacy of cancer immunotherapies (49). TGF-β negatively 
influences the activity of T lymphocytes and NK cells, inhibits 
maturation of DCs, and facilitates the recruitment of regulatory 
T cells (50). Likewise, immunosuppressive IL-10 is known to 
inhibit the function of APCs and generation of CTLs as well as 
suppress the activity and/or migration of CTLs (51).
Moreover, tumor cells can release enzymes that metabolize 
amino acids regulating activity of immune cells. One of such 
enzymes is indoleamine 2,3-dioxygenase (IDO), responsible for 
tryptophan catabolism. Enhanced expression of IDO in some 
types of tumors causes local shortage of tryptophan, leading 
to disturbances in proliferation of alloreactive T lymphocytes 
and their cell cycle arrest (52). Additionally, some tryptophan 
metabolites induce apoptosis in CD4+ T lymphocytes whereas 
kynurenine, a product of IDO-mediated tryptophan catabolism, 
leads to their differentiation into T regulatory cells (Tregs) that 
down-regulate immune response (53, 54).
Tumor cells that are unable to escape from immune recognition 
using the above mechanisms develop adaptation mechanisms to 
evade effector CTL-induced death. They can up-regulate expres-
sion of antiapoptotic molecules such as FLIP or BCL-XL (55, 
56). Otherwise, in order to avoid cell death, tumors can express 
inactive death receptors such as TRAIL-R1, TRAIL-R2, or FAS 
(57, 58).
immunosuppressive Cells
Together with tumor-intrinsic immune escape mechanisms 
described above, tumors may also highjack parts of the immune 
system to evade immune attack. To achieve this goal, they induce 
or recruit immune-suppressive Tregs as well as myeloid-derived 
suppressor cells (MDSC), which under normal conditions serve 
as safeguards against overwhelming inflammation. In this way, 
tumors turn the immune system against itself, and exercise 
a powerful arsenal of mechanisms unavailable to tumor cells 
themselves to mitigate anti-tumor immune activity. Tregs inhibit 
July 2015 | Volume 5 | Article 1764
Wachowska et al. Epigenetics and PDT in cancer immunotherapy
Frontiers in Oncology | www.frontiersin.org
activation and expansion of antigen-specific CD8+ T lympho-
cytes, through high expression of immune-inhibitory receptors 
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and 
PD-L1, secretion of immunosuppressive cytokines such as IL-10 
and TGF-β, and by consuming IL-2 (59). There are also other 
regulatory populations of lymphocytes that can be found among 
subsets of B cells and NKT cells inhibiting antitumor effector 
cell responses (60). MDSCs are heterogeneous population of 
cells originating from bone marrow including progenitor and 
immature myeloid cells of granulocytic or monocytic lineages 
(61). MDSCs engage several diverse strategies to suppress tumor 
growth by inhibiting tumor cell cytotoxicity mediated by NK 
cells and by blocking the activation of tumor-reactive CD4+ 
and CD8+ T cells (62, 63). These mechanisms include produc-
tion of immunosuppressive cytokines such as TGF-β and IL-10, 
production of reactive nitrogen and oxygen species, interference 
with T cell homing, and contribution to tumor angiogenesis 
(61, 63, 64). Moreover, MDSCs prevent antigen/MHC peptide 
recognition by nitrosylation of T cell receptor (TCR) and deplete 
amino acids such as tryptophan (IDO) or arginine (arginase-1) 
that are required for activation and proliferation of T cells (65). 
Additionally, MDSCs induce accumulation of Tregs, which in 
turn down-regulate cell-mediated immunity and promote a Th2 
type response that favors tumor progression (66).
The Role of epigenetic Changes in 
immune escape
Epigenetic mechanisms include post-translational modifica-
tions of histone proteins affecting chromatin remodeling, DNA 
methylation, and regulation of gene expression by non-coding 
RNAs. A number of epigenetic events seem to play a pivotal role 
both in tumor progression and in avoiding immune recognition 
(67, 68). The most widely studied and best understood in terms 
of modulating immunity are DNA methylation and histone 
modifications (Figure 1).
Methylation occurs predominantly in CpG-rich regions called 
“CpG islands.” A characteristic feature of tumor cells is global 
hypomethylation of their genome, and hypermethylation of CpG 
island in promoter regions of various genes (69). Methylation of 
DNA involves covalent addition of methyl group to C5 of cytosine 
ring leading to generation of 5-methylcytosine (70). Methylation 
of promoter regions leads to recruitment of methyl-CpG-binding 
proteins that form chromatin-remodeling co-repressor complexes 
resulting in gene silencing (67). Methylation pattern in every cell 
is established and maintained by a family of proteins called DNA 
methyltransferases (DNMTs).
Histones acetylation is a reversible process of adding an acetyl 
moiety to lysine residues on histone proteins resulting in neu-
tralization of their positive charge and impairing their interaction 
with negatively charged DNA. Therefore, acetylation increases the 
accessibility of regulatory proteins to DNA, enabling activation 
of various genes expression (71). This process may be reversed 
by the opposite activities of histones deacetylases (HDACs) that 
remove acetyl groups from histone proteins leading to recovery of 
N-terminal tail affinity to DNA strand. This results in chromatin 
condensation and suppression of transcription process.
influence of epigenetic Therapy on Tumor 
Antigen expression
DNA methylation is one of the most important epigenetic 
 mechanism regulating expression of genes responsible for 
recognition of tumor cells by host immune system. Particularly, 
this is relevant to methylation of gene promoters, which leads to 
silencing of TAA and APM proteins, enabling escape from tumor 
immune-surveillance (72).
The presence of TAA in cancer cells is a mandatory requirement 
for activation of effector CTLs. TAA can be divided into four different 
groups: (i) differentiation antigens, which are lineage-specific and 
expressed in tumor as well as in normal cells from which the tumors 
arise; (ii) overexpressed antigens, which are broadly expressed in 
many normal tissues, but present in tumor cells at higher levels; 
(iii) tumor-specific antigens, usually typical for individual tumors, 
resulting from genetic alterations; (iv) cancer–testis antigens (CTA) 
that are expressed in various types of malignant human tumors 
and are restricted in normal tissues to germ cells of the testis, with 
occasional expression in female reproductive organs (73). CTA 
are particularly susceptible to epigenetic regulation. They include 
melanoma-associated antigen (MAGE), NY-ESO-1, and SSX gene 
families as well as the GAGE/PAGE/XAGE superfamily. MAGE, 
GAGE, BAGE, SSX, and LAGE-1/NY-ESO-1 are frequently meth-
ylated and down-regulated in tumor cells. The CTA family also 
includes P1A antigen, one of the best known murine TAA, which 
is a homolog of human MAGE (74). P1A is an endogenous protein, 
initially identified in chemically induced mast cell-mastocytoma 
815 (75). As a classical CTA, P1A is not expressed in normal 
tissues, but expressed only in placenta and testis. P1A epitopes 
are presented to T lymphocytes through MHC H2-k2d and may 
induce strong specific response of CTLs (76). Similar to human 
MAGE gene family, in several murine tumors P1A is not expressed 
as a result of methylation of the promoter regions (77).
immunoregulatory effects of Drugs  
Targeting epigenetic Mechanisms
Drugs targeting epigenetic mechanisms can modulate expression 
of multiple genes including tumor suppressor genes, oncogenes, 
tumor associated antigens, as well as molecules involved in antigen 
presentation, co-stimulatory signaling and cytokines. Among dif-
ferent classes of genes described as epigenetically regulated, these 
encoding TAA are undoubtedly essential for T cell activation and 
tumor recognition by immune response. The expression of CTA 
can be restored by a number of hypomethylating agents (78, 79). 
Over 20 years ago, it was demonstrated that 5-aza-2′-deoxicitidyne 
(5-aza-dC) up-regulates MAGE-1 expression in tumor, but not in 
normal cells, and leads to HLA-A1-restricted lysis of tumor cells 
by CTLs (78). Further studies revealed that a variety of other CTA 
can be induced by either 5-aza-dC or other inhibitors of DNMTs 
(80–82). Methyltransferase inhibitors can also induce expression 
of MHC class I molecules. These effects result from the impact on 
both MHC genes as well as from regulation of virtually all com-
ponents of the APM, including TAP1 and 2, proteasome subunits 
(81, 83). Moreover, antigen presentation can be augmented by 
up-regulation of type I and II interferons, their receptors, and 
components of the IFN-signaling pathways (84). Importantly, the 
effects of methyltransferase inhibitors are long-lasting as CTA are 
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detectable for next several weeks after treatment and they are rec-
ognized by antigen-specific CD8+ T cells (77, 85, 86). Also histone 
deacetylase inhibitors (HDACi) may affect expression of TAA, 
but mostly by increasing or restoring expression level of proteins 
involved in antigen presentation. For example, trichostatin A (TCA) 
was shown to up-regulate or induce expression of TAP-1, TAP-2, 
tapasin, and LMP-2 in murine tumor cell lines (87, 88). Moreover, 
the TCA-mediated increase in MHC levels results in activation of 
adaptive immune response and inhibition of tumor growth in mice 
(88). Additionally, HDACi increase the expression of MHC class 
II and co-stimulatory molecules in human and mouse melanoma 
and trophoblast cell lines (89, 90). TCA, by means of activation of 
the pIII-CIITA promoter in neoplastic cells and induction of MHC 
class II expression, was also found to augment CD4+ T cells prolif-
eration (91). However, the result of their action is complex, since 
they down-regulate one antigen, Muc1, and up-regulate another, 
NY-ESO-1, at the same time (92). Based on these findings, a great 
deal of interest has been generated in investigation of epigenetic 
therapy influence on antitumor immune response.
It was also demonstrated that HDACi can affect polarization 
of naive CD4+ T cells toward Th1 and Th2 subsets. Vorinostat by 
inhibiting STAT6 and TARC may impair the functions of CD4+ 
T cells, shifting the balance toward Th1 response (93). Also hypo-
methylating agents increase production of cytokines, including 
IL-2, TNF, and IFN-γ (94, 95). Epigenetic treatment facilitates 
killing of tumor cells by NK cells or CTLs through up-regulation 
of TRAIL-R2 and FAS in transformed cells (96, 97). Furthermore, 
enhancement of NK-mediated tumor cell death was also induced 
by TCA by up-regulation of UL-16-binding protein expression (a 
ligand for cytotoxicity NKG2D receptor) (98).
Tumor Cell Recognition by immune 
System After Photodynamic Therapy 
enhanced by epigenetic Treatment
The still elusive goal for effective cancer immunotherapy is to 
overcome tumor escape mechanisms and to trigger development 
of systemic adaptive antitumor immune response allowing for the 
control of distant metastases. As described above, PDT is an effec-
tive local treatment that induces acute local inflammatory response. 
However, development of systemic adaptive immune response after 
PDT strongly depends on the efficacy of presentation and recogni-
tion of tumor antigens by the immune cells (1). Various approaches 
have been examined to accelerate the priming phase of immune 
response after PDT. Induction of antitumor activity depends on 
activation of CD8+ T cells and administration of immature DCs into 
the PDT-treated tumors resulted in effective activation of T and NK 
cells (24). Also, the PDT effectiveness was improved by administra-
tion of adjuvants, such as glycated chitosan (99). Additionally, the 
FiGURe 1 | immunoregulatory mechanisms of epigenetic treatment. 
(A) The influence of HDACi and hypomethylating drugs on APC presentation 
of TAA as well as activation and proliferation of T cell in lymph nodes.  
(B) Immune response in the tumors can be improved by epigenetic 
treatment by augmenting T and NK cell cytotoxicity and secretion of TNF 
and IFN-γ.
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role of expression level of MHC class I in PDT was evaluated in the 
treatment of patients with vulval intraepithelial neoplasia (VIN). 
In VIN lesions that respond to PDT, significant increase of CD8+ 
infiltration after treatment was observed when compared to non-
responders. Interestingly, none of responding VIN patients showed 
any evidence of MHC class I down-regulation, whereas all of the 
cases of VIN lacking of MHC I failed to respond to PDT (100).
One of the approaches to increase immunogenicity of tumor 
cells focused on their genetic modification to enhance activation 
of CTLs by DCs. Introduction of foreign antigen, such as green 
fluorescence protein (GFP) to radiation-induced fibrosarcoma 
cells was observed to induce strong tumor-specific immune 
response allowing for long-term tumor control. Re-challenge 
experiments revealed that survived mice developed resistance 
to GFP-positive cells (101). These data are in line with another 
study demonstrating that the presence of β-galactosidase antigen 
in tumor cells is able to increase immunogenicity allowing PDT 
to elicit strong antitumor effects and long-term immunity to re-
inoculated tumor cells (102). In this vein, the same authors have 
transfected tumor cells with a gene encoding P1A, a model CTA in 
the mouse. The presence of this antigen led to effective antitumor 
immune response that only developed when PDT was used and 
was found sufficient to prevent tumor growth when tumor cells 
were re-inoculated (74). Moreover, PDT was shown to enhance 
systemic immune responses to tumors in patients with Basal cell 
carcinoma. The immune recognition of cancer cell antigen – Hip 
1 – was improved by PDT treatment (103).
Considering that 5-aza-dC restores expression of CTA 
including P1A as well as MHC class I molecules (77), we sought 
to evaluate the antitumor effects of the combined treatment 
involving PDT and administration of 5-aza-dC. We have observed 
that treatment with 5-aza-dC alone restores expression of MHC 
class I molecules as well as induces expression of P1A antigen 
in four different murine tumor models and two strains of mice 
(104). Antitumor effects of 5-aza-dC were rather insignificant 
when used alone. However, when we combined 5-aza-dC with 
PDT, we observed prolonged complete antitumor responses in 
mice with EMT6 mammary tumors and CT26 colon adenocar-
cinomas and significant prolongation of survival in mice bearing 
4T1 mammary tumors and LLC lung carcinomas. The antitumor 
effects of the combination treatment were strongly dependent on 
the presence of CD8+ CTLs as their depletion with monoclonal 
antibodies almost completely abrogated antitumor effects. On 
the other hand, CD4+ T cells played only a supportive role. We 
have also observed that the combined treatment led to expansion 
of IL-17-producing CD4+ T cells, which are known to stimulate 
CD8+. Intriguingly, pentamer staining for P1A-specific CD8+ 
T cell population revealed no significant changes in draining 
LNs and spleens between experimental groups. Moreover, all 
mice treated with PDT and 5-aza-dC that remained long-term 
tumor-free have rejected re-inoculated tumor cells even if the 
cells were P1A-negative. These findings suggest that the pres-
ence of P1A is not essential for the maintenance of long-lasting 
antitumor immunity. It is possible that 5-aza-dC combined with 
PDT may lead to increased expression and release of TAA in the 
PDT-treated microenvironment. Together with PDT-induced 
inflammation and the release of DAMPs, the combination 
treatment would confer better antigen presentation of P1A. 
Improved tumor recognition by immune cells can further expand 
the repertoire of antigen-specific T cells thereby increasing the 
FiGURe 2 | Activation of antigen-specific antitumor immune response 
by photodynamic therapy (PDT). 5-aza-2′-deoxycitidine (5-aza-dC) 
up-regulates expression of silenced tumor-associated antigens (TAA). PDT leads 
to the release of TAA that are further phagocytosed by attracted to the tumor 
lesion of immature dendritic cells (DCs). Activated DCs migrate to local lymph 
nodes and present TAA-derived peptides in association with MHC molecules to 
T lymphocytes. T cells are activated and subsequently differentiate into effector 
cells homing to the tumor site in order to destroy residual tumor cells.
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immunogenic outcome of PDT. Thus, it can be hypothesized that 
PDT of tumors with TAAs up-regulated by 5-aza-dC can induce 
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weakly immunogenic antigens and facilitate epitope spreading. 
Immunity to the latter can sustain antitumor activity in mice. To 
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5-aza-dC with PDT leads to local cytotoxic effects accompanied 
by the release of induced TAAs allowing for development of 
antitumor immune response and long-term survival (Figure 2). 
Based on these findings, we hypothesize that inhibition of DNA 
methylation could unleash stronger immune response against 
TAA in tumor-bearing mice undergoing PDT.
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